10.62
0.09 (0.85%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | Harrow, Inc. | Bearish | Bearish |
Analyst Consensus
2 Buy
Avg. Price @ Call: 12.60
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| 52 Weeks Range |
7.60 - 28.25
|
|
| Price Target Range | ||
| High | 26.00 (B. Riley Securities, 144.82%) | Buy |
| Median | 25.00 (135.40%) | |
| Low | 24.00 (Craig-Hallum, 125.99%) | Buy |
| Average | 25.00 (135.40%) | |
| Total | 2 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 11 Apr 2024 | 24.00 (125.99%) | Buy | 13.19 |
| B. Riley Securities | 25 Mar 2024 | 26.00 (144.82%) | Buy | 12.00 |
| 22 Mar 2024 | 26.00 (144.82%) | Buy | 11.50 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 May 2024 | Announcement | Harrow to Present at Two Investor Conferences in May |
| 13 May 2024 | Announcement | Harrow Announces First Quarter 2024 Financial Results |
| 13 May 2024 | Announcement | Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial |
| 25 Apr 2024 | Announcement | Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 |
| 02 Apr 2024 | Announcement | Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing |
| 19 Mar 2024 | Announcement | Harrow Announces Fourth Quarter and Year-End 2023 Financial Results |
| 05 Mar 2024 | Announcement | Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 |
| 15 Feb 2024 | Announcement | Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |